2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-N-(3-methyl-isothiazol-5-yl)-2-oxo-acetamide | 501921-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-N-(3-methyl-isothiazol-5-yl)-2-oxo-acetamide
• 英文别名: 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide
• CAS: 501921-56-8
• 化学式: C₂₁H₁₆ClN₃O₂S
• 分子量: 409.896
• InChiKey: CIVZDTWEDJCTJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  92.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-N-(3-methyl-isothiazol-5-yl)-2-oxo-acetamide 、 盐酸羟胺 、 sodium acetate 、 在 2-[1-(4-Chloro-benzyl)-1H-indol-3-yl]-2-hydroxyimino-N-(3-methyl-isothiazol-5-yl)-acetamide 、 水 作用下， 以 乙醇 、 四氢呋喃 为溶剂， 反应 72.0h， 生成 2-[1-(4-Chloro-benzyl)-1H-indol-3-yl]-2-hydroxyimino-N-(3-methyl-isothiazol-5-yl)-acetamide
  参考文献：
  名称：

  3-glyoxylamideindoles for treating cancer

  摘要：

  本发明公开了一种抗癌化合物，其化学结构式表示为(I)：结构式(I)中的变量在下文中描述。本发明还公开了一种制药组合物，包括一种药学上可接受的载体或稀释剂和一种化合物，所述化合物表示为结构式(I)（优选为有效量）。本发明还公开了一种通过向患有癌症的受试者投与一种表示为结构式(I)的化合物的有效量来治疗受试者的方法。

  公开号：

  US06958348B2
• 作为产物：
  描述：

  3-甲基异噻唑-5-胺 、 2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-2-oxoacetyl chloride 在 TEA 作用下， 以 四氢呋喃 为溶剂， 以1.49 g的产率得到2-[1-(4-chlorobenzyl)-1H-indol-3-yl]-N-(3-methyl-isothiazol-5-yl)-2-oxo-acetamide
  参考文献：
  名称：

  Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines

  摘要：

  We report herein the SAR studies of a series of indole- and indolizine-glyoxylamides that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance ( MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types of various origins ( e. g., breast, colon, uterine). (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.02.029

文献信息

• 3-glyoxlylamideindoles for treating cancer
  申请人：SBR Pharmaceuticals Corp.

  公开号：US20030092751A1

  公开（公告）日：2003-05-15

  Disclosed is an anti-cancer compound represented by Structural Formula (I): 1 The variables in Structural Formula (I) are described hereinbelow. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferably an effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).

  本发明公开了一种抗癌化合物，其结构式表示为（I）：1。结构式（I）中的变量在下文中描述。本发明还公开了一种制药组合物，包括一种药用可接受载体或稀释剂和一种结构式（I）所表示的化合物（优选为有效量）。本发明还公开了一种通过向患有癌症的受试者施用一种结构式（I）所表示的化合物的有效量来治疗患者的方法。
• 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1427416A2

  公开（公告）日：2004-06-16
• US6958348B2
  申请人：——

  公开号：US6958348B2

  公开（公告）日：2005-10-25
• [EN] 3-GLYOXLYLAMIDEINDOLES FOR TREATING CANCER<br/>[FR] 3-GLYOXLYLAMIDE-INDOLES POUR TRAITEMENT DU CANCER
  申请人：SBR PHARMACEUTICALS CORP

  公开号：WO2003022280A2

  公开（公告）日：2003-03-20

  Disclosed is an anti-cancer compound represented by Structural Formula (I). The variables in Structural Formula (I) are described herein. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Structural Formula (I) (preferablyan effective amount). Also disclosed is a method of treating a subject with cancer by administering to the subject an effective amount of a compound represented by Structural Formula (I).
• Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines
  作者：David A. James、Keizo Koya、Hao Li、Guiqing Liang、Zhiqiang Xia、Weiwen Ying、Yaming Wu、Lijun Sun

  DOI：10.1016/j.bmcl.2008.02.029

  日期：2008.3

  We report herein the SAR studies of a series of indole- and indolizine-glyoxylamides that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance ( MDR) phenotypes. The in vitro cytotoxic effects have been demonstrated across a wide array of tumor types of various origins ( e. g., breast, colon, uterine). (C) 2008 Elsevier Ltd. All rights reserved.